2024
Synergistic effects of sulopenem in combination with cefuroxime or durlobactam against Mycobacterium abscessus
Dousa K, Shin E, Kurz S, Plummer M, Nantongo M, Bethel C, Taracila M, Nguyen D, Kreiswith B, Daley C, Remy K, Holland S, Bonomo R. Synergistic effects of sulopenem in combination with cefuroxime or durlobactam against Mycobacterium abscessus. MBio 2024, 15: e00609-24. PMID: 38742824, PMCID: PMC11237399, DOI: 10.1128/mbio.00609-24.Peer-Reviewed Original ResearchConceptsD,D-carboxypeptidaseMinimum inhibitory concentrationB-lactamPenicillin-binding-proteinCell wall synthesisL,D-transpeptidasesResistance to common antibioticsLowest minimum inhibitory concentrationWall synthesisCystic fibrosisD-carboxypeptidaseMass spectrometry analysisB-lactamaseThioester bondRate of treatment failureCell-based assaysMultiple antibioticsB-lactam ringsCommon antibioticsD-transpeptidasesB-lactamase inhibitorsCysteine residuesTime-kill studiesStructural lung diseaseMultidrug-resistant tuberculosisThe recent rapid expansion of multidrug resistant Ural lineage Mycobacterium tuberculosis in Moldova
Chitwood M, Colijn C, Yang C, Crudu V, Ciobanu N, Codreanu A, Kim J, Rancu I, Rhee K, Cohen T, Sobkowiak B. The recent rapid expansion of multidrug resistant Ural lineage Mycobacterium tuberculosis in Moldova. Nature Communications 2024, 15: 2962. PMID: 38580642, PMCID: PMC10997638, DOI: 10.1038/s41467-024-47282-9.Peer-Reviewed Original ResearchConceptsMDR M. tuberculosisGenome sequenceResistance-conferring mutationsBeijing sublineageMDR strainsReproductive fitnessBeijing strainsCulture-positive casesLineagesMTB strainsMultidrug-resistant tuberculosisMDRMtbStrainMDR-TBMutationsResistant tuberculosisMDR-MTBSubstantial riskSublineagesTuberculosisSequenceIdentifying local foci of tuberculosis transmission in Moldova using a spatial multinomial logistic regression model
Lan Y, Crudu V, Ciobanu N, Codreanu A, Chitwood M, Sobkowiak B, Warren J, Cohen T. Identifying local foci of tuberculosis transmission in Moldova using a spatial multinomial logistic regression model. EBioMedicine 2024, 102: 105085. PMID: 38531172, PMCID: PMC10987885, DOI: 10.1016/j.ebiom.2024.105085.Peer-Reviewed Original ResearchConceptsPatterns of spatial aggregationMTB strainsMDR-TBLogistic regression modelsGenome Epidemiology StudySpecific strainsMultidrug-resistant tuberculosisTreated TB casesNational Institute of AllergyMDR phenotypeRegression modelsM. tuberculosisInstitute of AllergyMultinomial logistic regression modelUS National Institutes of HealthNational Institutes of HealthMDR diseasePublic health concernAssociated with local transmissionIncident TBInstitutes of HealthMtbResistant tuberculosisStrainDiagnosing TBBrief Report: Differentiated Service Delivery Framework for People With Multidrug-Resistant Tuberculosis and HIV Coinfection
Reis K, Wolf A, Perumal R, Seepamore B, Guzman K, Ross J, Cheung Y, Amico K, Brust J, Padayatchi N, Friedland G, Naidoo K, Daftary A, Zelnick J, O'Donnell M. Brief Report: Differentiated Service Delivery Framework for People With Multidrug-Resistant Tuberculosis and HIV Coinfection. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2024, 96: 34-39. PMID: 38323838, PMCID: PMC11300702, DOI: 10.1097/qai.0000000000003394.Peer-Reviewed Original ResearchMultidrug-resistant tuberculosisDifferentiated service deliveryAntiretroviral therapyElectronic dose monitoring devicesAntiretroviral therapy adherenceMultidrug-resistant tuberculosis treatmentDifferentiated service delivery modelsHIV Co-InfectionTreatment courseCumulative adherenceTreatment challengesCo-InfectionBedaquilineTreatment completionFocus groupsMedication adherenceHIVTreatmentPatterns of medication adherenceAdherenceTuberculosisSubpopulationsHIV/AIDSTreatment stageStage-specific
2023
Adaptive evaluation of mHealth and conventional adherence support interventions to optimize outcomes with new treatment regimens for drug-resistant tuberculosis and HIV in South Africa (ADAP-TIV): study protocol for an adaptive randomized controlled trial
Ross J, Perumal R, Wolf A, Zulu M, Guzman K, Seepamore B, Reis K, Nyilana H, Hlathi S, Narasimmulu R, Cheung Y, Amico K, Friedland G, Daftary A, Zelnick J, Naidoo K, O’Donnell M. Adaptive evaluation of mHealth and conventional adherence support interventions to optimize outcomes with new treatment regimens for drug-resistant tuberculosis and HIV in South Africa (ADAP-TIV): study protocol for an adaptive randomized controlled trial. Trials 2023, 24: 776. PMID: 38037105, PMCID: PMC10691086, DOI: 10.1186/s13063-023-07520-9.Peer-Reviewed Original ResearchConceptsMultidrug-resistant tuberculosisAdherence support interventionsAntiretroviral therapyTreatment regimensAdherence supportPrimary outcomeTreatment supportPsychosocial supportMDR-TB treatment regimensUndetectable HIV viral loadSupport interventionsIntegrase strand transfer inhibitorsAdherence support strategiesComposite clinical outcomeMDR-TB regimensNegative TB culturesCombination antiretroviral therapyComposite primary outcomeHIV treatment outcomesHIV viral loadDrug-resistant tuberculosisStandard of careNew treatment regimensDifferentiated service deliveryStrand transfer inhibitors
2022
Bedaquiline Adherence Measured by Electronic Dose Monitoring Predicts Clinical Outcomes in the Treatment of Patients With Multidrug-Resistant Tuberculosis and HIV/AIDS
O'Donnell MR, Padayatchi N, Wolf A, Zelnick J, Daftary A, Orrell C, Nimmo C, Baldwin M, Boodhram R, Maharaj B, Amico KR, Naidoo K, Friedland G. Bedaquiline Adherence Measured by Electronic Dose Monitoring Predicts Clinical Outcomes in the Treatment of Patients With Multidrug-Resistant Tuberculosis and HIV/AIDS. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2022, 90: 325-332. PMID: 35195572, PMCID: PMC11077859, DOI: 10.1097/qai.0000000000002940.Peer-Reviewed Original ResearchConceptsMDR-TB treatment outcomesResistance-associated variantsTreatment outcomesAntiretroviral therapyMDR-TBART adherenceMultidrug-resistant tuberculosis treatmentHIV treatment outcomesProspective cohort studyMultidrug-resistant tuberculosisEnd of treatmentTreatment of patientsSuccessful treatment outcomeElectronic dose monitoring devicesHIV/AIDSCohort studyClinical outcomesMultivariable analysisNovel regimensMedication adherenceAdherence thresholdTuberculosis treatmentTreatment completionLow adherenceDose monitoringAdherence Measured Using Electronic Dose Monitoring is Associated with Emergent Antiretroviral Resistance and Poor Outcomes in People with Human Immunodeficiency Virus/AIDS and Multidrug-Resistant Tuberculosis
Bateman M, Wolf A, Chimukangara B, Brust JCM, Lessells R, Amico R, Boodhram R, Singh N, Orrell C, Friedland G, Naidoo K, Padayatchi N, O’Donnell MR. Adherence Measured Using Electronic Dose Monitoring is Associated with Emergent Antiretroviral Resistance and Poor Outcomes in People with Human Immunodeficiency Virus/AIDS and Multidrug-Resistant Tuberculosis. Clinical Infectious Diseases 2022, 75: 1489-1496. PMID: 35352097, PMCID: PMC9617578, DOI: 10.1093/cid/ciac232.Peer-Reviewed Original ResearchConceptsMultidrug-resistant tuberculosisHuman immunodeficiency virusMDR-TB treatmentART adherenceART resistanceHuman immunodeficiency virus/AIDSEmergent resistanceStandard of careResource-limited settingsTB regimensAntiretroviral resistanceHIV RNAProspective cohortMedication adherenceImmunodeficiency virusPoor outcomeShort followAdherence thresholdCopies/Treatment outcomesDose monitoringResistance mutationsResistance testingPublic hospitalsLinear associationPhylogeography and transmission of M. tuberculosis in Moldova: A prospective genomic analysis
Yang C, Sobkowiak B, Naidu V, Codreanu A, Ciobanu N, Gunasekera KS, Chitwood MH, Alexandru S, Bivol S, Russi M, Havumaki J, Cudahy P, Fosburgh H, Allender CJ, Centner H, Engelthaler DM, Menzies NA, Warren JL, Crudu V, Colijn C, Cohen T. Phylogeography and transmission of M. tuberculosis in Moldova: A prospective genomic analysis. PLOS Medicine 2022, 19: e1003933. PMID: 35192619, PMCID: PMC8903246, DOI: 10.1371/journal.pmed.1003933.Peer-Reviewed Original ResearchConceptsMultidrug-resistant tuberculosisDrug-resistant M. tuberculosisM. tuberculosis strainsPutative transmission clustersM. tuberculosisTransmission clustersMultidrug-resistant M. tuberculosis strainsTuberculosis strainsMultiple M. tuberculosis strainsCulture-positive TB casesLocal transmissionMDR-TB epidemicDrug-susceptible tuberculosisDrug resistance mutationsDrug resistance profilesUrgency of interventionTB casesDemographic dataNew casesTuberculosisInadequate treatmentNatural historyResistance mutationsBeijing lineageMycobacterium tuberculosis
2021
Rifampicin-Monoresistant Tuberculosis Is Not the Same as Multidrug-Resistant Tuberculosis: a Descriptive Study from Khayelitsha, South Africa
Salaam-Dreyer Z, Streicher EM, Sirgel FA, Menardo F, Borrell S, Reinhard M, Doetsch A, Cudahy PGT, Mohr-Holland E, Daniels J, Dippenaar A, Nicol MP, Gagneux S, Warren RM, Cox H. Rifampicin-Monoresistant Tuberculosis Is Not the Same as Multidrug-Resistant Tuberculosis: a Descriptive Study from Khayelitsha, South Africa. Antimicrobial Agents And Chemotherapy 2021, 65: 10.1128/aac.00364-21. PMID: 34460307, PMCID: PMC8522772, DOI: 10.1128/aac.00364-21.Peer-Reviewed Original ResearchConceptsMultidrug-resistant TBRMR-TBRR-TBPatient-level clinical dataPhenotypic drug susceptibility testingRifampicin-monoresistant tuberculosisRR-TB patientsMultidrug-resistant tuberculosisHIV-positive individualsRifampin-resistant tuberculosisDrug susceptibility testingRifampin monoresistanceHIV infectionMDR isolatesTB drugsRisk factorsClinical dataSusceptibility testingSubset of isolatesTuberculosisDescriptive studyMycobacterium tuberculosisAvailable WGS dataSignificant differencesPatients
2020
Time to sputum culture conversion and its predictors among patients with multidrug-resistant tuberculosis in Hangzhou, China
Li Q, Lu M, Hsieh E, Wu L, Wu Y, Wang M, Wang L, Zhao G, Xie L, Qian HZ. Time to sputum culture conversion and its predictors among patients with multidrug-resistant tuberculosis in Hangzhou, China. Medicine 2020, 99: e23649. PMID: 33327347, PMCID: PMC7738096, DOI: 10.1097/md.0000000000023649.Peer-Reviewed Original ResearchConceptsInitial sputum culture conversionSputum culture conversionPoor treatment outcomesSuccessful treatment outcomeTreatment outcomesCulture conversionMDR-TBMultidrug-resistant tuberculosis patientsCox proportional hazards regressionMDR-TB treatmentMDR-TB patientsRetrospective cohort studyKaplan-Meier methodTreatment success rateInitiation of treatmentMultidrug-resistant tuberculosisProportional hazards regressionConsecutive negative culturesRisk of transmissionCohort studyTuberculosis patientsTreatment failureHazards regressionOutpatient treatmentInpatient treatmentTreatment Guidelines for Active Drug-Susceptible and Drug-Resistant Pulmonary Tuberculosis, and Latent Tuberculosis Infection
Sosa L, Friedman L. Treatment Guidelines for Active Drug-Susceptible and Drug-Resistant Pulmonary Tuberculosis, and Latent Tuberculosis Infection. 2020, 393-398. DOI: 10.1201/9781351249980-20.Peer-Reviewed Original ResearchExtensively Drug-Resistant TuberculosisInjectable agentsThree-drug regimensResistance to isoniazidMultidrug-resistant tuberculosisUnited States Food and Drug AdministrationLatent tuberculosis infectionDrug-resistant tuberculosisStates Food and Drug AdministrationDrug-sensitive tuberculosisFood and Drug AdministrationPulmonary tuberculosisSensitive to isoniazidDrug susceptibilityResistant TBTuberculosis infectionTreatment guidelinesDrug AdministrationRifampinWorld Health OrganizationTuberculosisIsoniazidRegimensMonthsTreatmentThe Impact of Concurrent Antiretroviral Therapy and MDR-TB Treatment on Adverse Events.
Smith JP, Gandhi NR, Shah NS, Mlisana K, Moodley P, Johnson BA, Allana S, Campbell A, Nelson KN, Master I, Brust JCM. The Impact of Concurrent Antiretroviral Therapy and MDR-TB Treatment on Adverse Events. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2020, 83: 47-55. PMID: 31809360, PMCID: PMC6903405, DOI: 10.1097/qai.0000000000002190.Peer-Reviewed Original ResearchConceptsMultidrug-resistant tuberculosisConcurrent antiretroviral therapyMDR-TB patientsMDR-TB treatmentLaboratory adverse eventsAdverse eventsHIV coinfectionAntiretroviral therapyHIV statusConcurrent treatmentCommon clinical adverse eventsCommon laboratory adverse eventsCo-infected participantsColor discrimination testingMDR-TB therapyAntiretroviral therapy initiationFrequent adverse eventsClinical adverse eventsProspective observational studyFavorable treatment outcomesColor discrimination lossesTherapy initiationConcurrent therapyCreatinine clearanceVision loss
2019
Transmissibility and potential for disease progression of drug resistant Mycobacterium tuberculosis: prospective cohort study
Becerra MC, Huang CC, Lecca L, Bayona J, Contreras C, Calderon R, Yataco R, Galea J, Zhang Z, Atwood S, Cohen T, Mitnick CD, Farmer P, Murray M. Transmissibility and potential for disease progression of drug resistant Mycobacterium tuberculosis: prospective cohort study. The BMJ 2019, 367: l5894. PMID: 31649017, PMCID: PMC6812583, DOI: 10.1136/bmj.l5894.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAntitubercular AgentsChildChild, PreschoolContact TracingDisease ProgressionFemaleFollow-Up StudiesHumansIncidenceInfantInfant, NewbornIsoniazidKaplan-Meier EstimateMaleMicrobial Sensitivity TestsMiddle AgedMycobacterium tuberculosisPeruProspective StudiesRifampinSputumTuberculin TestTuberculosis, Multidrug-ResistantTuberculosis, PulmonaryYoung AdultConceptsDrug-sensitive tuberculosisMultidrug-resistant tuberculosisHousehold contactsProspective cohort studySensitive tuberculosisTuberculosis infectionResistant tuberculosisCohort studyTuberculosis diseaseHigh riskDrug-resistant Mycobacterium tuberculosisIncident tuberculosis diseasePhenotypic drug resistanceDistrict Health CenterResistant Mycobacterium tuberculosisDrug-susceptible strainsDrug resistance profilesActive diseasePulmonary tuberculosisDisease progressionGuideline producersHealth centersIndex patientsEffective treatmentPatients
2018
Investigating spillover of multidrug-resistant tuberculosis from a prison: a spatial and molecular epidemiological analysis
Warren JL, Grandjean L, Moore DAJ, Lithgow A, Coronel J, Sheen P, Zelner JL, Andrews JR, Cohen T. Investigating spillover of multidrug-resistant tuberculosis from a prison: a spatial and molecular epidemiological analysis. BMC Medicine 2018, 16: 122. PMID: 30071850, PMCID: PMC6091024, DOI: 10.1186/s12916-018-1111-x.Peer-Reviewed Original Research
2017
Improved Survival and Cure Rates With Concurrent Treatment for Multidrug-Resistant Tuberculosis–Human Immunodeficiency Virus Coinfection in South Africa
Brust JCM, Shah NS, Mlisana K, Moodley P, Allana S, Campbell A, Johnson BA, Master I, Mthiyane T, Lachman S, Larkan LM, Ning Y, Malik A, Smith JP, Gandhi NR. Improved Survival and Cure Rates With Concurrent Treatment for Multidrug-Resistant Tuberculosis–Human Immunodeficiency Virus Coinfection in South Africa. Clinical Infectious Diseases 2017, 66: 1246-1253. PMID: 29293906, PMCID: PMC5888963, DOI: 10.1093/cid/cix1125.Peer-Reviewed Original ResearchConceptsCells/mm3Immunodeficiency virus coinfectionAntiretroviral therapyMDR tuberculosisCD4 countVirus coinfectionConcurrent treatmentTreatment outcomesHuman immunodeficiency virus (HIV) coinfectionUndetectable HIV viral loadConcurrent antiretroviral therapyMDR tuberculosis patientsHIV viral loadMultidrug-resistant tuberculosisStrong risk factorTuberculosis-HIVTuberculosis outcomesAdverse eventsTuberculosis patientsImproved survivalMedian agePrimary outcomeHIV statusViral loadCure rateCatastrophic costs potentially averted by tuberculosis control in India and South Africa: a modelling study
Verguet S, Riumallo-Herl C, Gomez GB, Menzies NA, Houben RMGJ, Sumner T, Lalli M, White RG, Salomon JA, Cohen T, Foster N, Chatterjee S, Sweeney S, Baena IG, Lönnroth K, Weil DE, Vassall A. Catastrophic costs potentially averted by tuberculosis control in India and South Africa: a modelling study. The Lancet Global Health 2017, 5: e1123-e1132. PMID: 29025634, PMCID: PMC5640802, DOI: 10.1016/s2214-109x(17)30341-8.Peer-Reviewed Original ResearchConceptsMultidrug-resistant tuberculosisEnd TB StrategyTuberculosis servicesCatastrophic costsTB StrategyDrug-sensitive tuberculosisCatastrophic financial burdenAnnual household incomeTuberculosis careTuberculosis controlEconomic burdenTuberculosisIntervention effectsMelinda Gates FoundationHousehold incomeIndirect costsFinancial burdenExpansion of accessPatientsTotal annual household incomeTreatmentCareGates FoundationBurdenIntervention scenariosPopulation implications of the use of bedaquiline in people with extensively drug-resistant tuberculosis: are fears of resistance justified?
Kunkel A, Furin J, Cohen T. Population implications of the use of bedaquiline in people with extensively drug-resistant tuberculosis: are fears of resistance justified? The Lancet Infectious Diseases 2017, 17: e429-e433. PMID: 28533094, DOI: 10.1016/s1473-3099(17)30299-2.Peer-Reviewed Original ResearchConceptsUse of bedaquilineDrug-resistant tuberculosisXDR tuberculosisBedaquiline resistanceCohort study resultsMultidrug-resistant tuberculosisNew combination regimensHigh mortality rateFears of resistanceInfected contactsCombination regimensDrug combinationsPatientsEquivalent outcomesMortality rateAntituberculosis drugsBedaquilineTuberculosisNovel drugsDrug bedaquilineDrugsDiseasePopulation implicationsResistance concernsGreat needAccuracy of line probe assays for the diagnosis of pulmonary and multidrug-resistant tuberculosis: a systematic review and meta-analysis
Nathavitharana RR, Cudahy PG, Schumacher SG, Steingart KR, Pai M, Denkinger CM. Accuracy of line probe assays for the diagnosis of pulmonary and multidrug-resistant tuberculosis: a systematic review and meta-analysis. European Respiratory Journal 2017, 49: 1601075. PMID: 28100546, PMCID: PMC5898952, DOI: 10.1183/13993003.01075-2016.Peer-Reviewed Original ResearchConceptsLine probe assayComposite reference standardINH resistanceRIF resistanceSystematic reviewMultidrug-resistant tuberculosis (MDR-TB) casesRapid drug susceptibility testingMultidrug-resistant tuberculosisProbe assayTuberculosis detectionDrug susceptibility testingSmear-positive specimensSmear-negative specimensReference standardM. tuberculosis detectionMycobacterium tuberculosis detectionPulmonary TBTuberculosis casesNew line probe assayStudy qualityIsoniazid resistanceQUADAS-2Indirect testingRifampicinUnique studies
2016
Assessing Local Risk of Rifampicin-Resistant Tuberculosis in KwaZulu-Natal, South Africa Using Lot Quality Assurance Sampling
Heidebrecht CL, Podewils LJ, Pym A, Mthiyane T, Cohen T. Assessing Local Risk of Rifampicin-Resistant Tuberculosis in KwaZulu-Natal, South Africa Using Lot Quality Assurance Sampling. PLOS ONE 2016, 11: e0153143. PMID: 27050561, PMCID: PMC4822784, DOI: 10.1371/journal.pone.0153143.Peer-Reviewed Original ResearchConceptsIncident TB casesTB casesResistant TBDrug-resistant TB casesRifampicin-resistant tuberculosisMultidrug-resistant tuberculosisDrug susceptibility testingRIF-resistant TBLot Quality Assurance SamplingQuality assurance samplingResistant diseaseHigh burdenRIF resistanceKwaZulu-NatalSusceptibility testingHigh-risk areasTuberculosisRiskGreater proportionBurdenTBDiseaseGeographic heterogeneityCasesRifampicin
2015
Fitness Costs of Drug Resistance Mutations in Multidrug-Resistant Mycobacterium tuberculosis: A Household-Based Case-Control Study
Salvatore PP, Becerra MC, Wiesch P, Hinkley T, Kaur D, Sloutsky A, Cohen T. Fitness Costs of Drug Resistance Mutations in Multidrug-Resistant Mycobacterium tuberculosis: A Household-Based Case-Control Study. The Journal Of Infectious Diseases 2015, 213: 149-155. PMID: 26092854, PMCID: PMC4676541, DOI: 10.1093/infdis/jiv347.Peer-Reviewed Original ResearchConceptsDrug resistance mutationsCase-control studyKatG Ser315Thr mutationMDR strainsMultiple case householdsResistance mutationsDrug resistance-associated mutationsMycobacterium tuberculosisMultidrug-resistant Mycobacterium tuberculosisSecondary household casesSer315Thr mutationMDR M. tuberculosisMultidrug-resistant tuberculosisMDR Mycobacterium tuberculosisResistance-associated polymorphismsLong-term prevalenceResistance-associated mutationsVivo fitness costsCase-control designEpidemiologic studiesHousehold casesTuberculosisExperimental modelM. tuberculosisMutations
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply